Integrin alpha5beta1 jako therapeutický cíl v léčbě mozkových nádorů

Bartík, Petr

INTRODUCTION Cancer is a leading cause of death in Europe taking yearly about 1.7 million of lives. Modern medicine hav! made considerable progress in treatment of some type of cancer such as cancers of prostate, breast and skin with the 5-years survival rate óver 90%o. However. current treatment options (surgery, radiotherapy, chemotherapy) are apparently less effective against other kinds of"uncli with bad prognosis such as cancer of lung and brain. Some of the most lethal cancers are high gňa" gliomas, which account for the most of cerebral tuňo,.. Ťn.y u.. djft.."' rapidly growing' highly inťrltrative and abundantly vascularized. These óháracteristics together with the delicate place of their incidence result in bad prognosis oť patients diagnosed with these cancers (Lefranc et al., 2006). Despite some recent advances the current non-targeted therapies only slightly improve patients post diagnosis survival rates ňd -aggróssive gliomas remain incurable disease. That is wtry tňJneuro- oncologists call for novel and more efficient treatment modalities. The hallmarks of tumor progression are the capacities of tumor cells to multiply rapidly, invade 'urrounáing tissue and stimulate endothelial cells to form new vasculature to nourish them. Therefore the aims of novel therapies should be to block the...

host :: přihlásit Digitální repozitář
		Hledej		Nový záznam		Nápověda		O repozitáři